Controlled, Large-Scale Manufacturing of hiPSC-Derived Cardiomyocytes

22 May 2019

In this application note, Eppendorf discusses how functional human cardiomyocytes, derived from a diverse set of disease hiPSC lines, can be manufactured at a large scale using a controlled, stirred-tank bioreactor approach.

Links

Tags